Recent news on Clopidogrel Bisulfate

sanofi-aventis: Full-year Guidance Raised on Good 2007 First ...  -  May 3, 2007
MSN MoneyOn August 8, 2006, Apotex announced that it had launched a generic version of clopidogrel bisulfate 75 mg tablets in competition with Plavix(R) in the

Bristol-Myers Squibb Company Reports First Quarter 2007 Financial ...  -  26 Apr 2007
PharmaLive.com (press release),This was due to the impact of residual sales of generic clopidogrel bisulfate, partially offset by the replenishment of branded PLAVIX® inventory in the

Bristol Names Cornelius Chief, Beats Profit Estimates (Update2)  -  26 Apr 2007
BloombergBristol- Myers and its marketing partner, France's Sanofi-Aventis SA, said the patent covers the main ingredient in Plavix, clopidogrel bisulfate.

A dent on the viablility of DES usage  -  Mar 23, 2007
Daily News & Analysis,Plavix (clopidogrel bisulfate) is widely used blood-thinning drug. Dr GR Kane, Interventional cardiologist, Hinduja Hospital, Mumbai, agrees that there are

Pharmas to lose $100bn to generics  -  Feb 23, 2007
DrugResearcher.com,Plavix (clopidogrel bisulfate) drop 90 per cent within a quarter as generic clopidogrel hit the market following the branded product's patent expiry.

Pharmas to lose $100bn to generics  -  Feb 22, 2007
In-PharmaTechnologist.com,Eli Lilly experienced this first hand on patent expiration of Prozac (fluoxetine), and Bristol-Myers Squibb saw revenues for Plavix (clopidogrel bisulfate)

Bristol-Myers, Sanofi Trial Over Plavix Patent Ends in New York  -  Feb 15, 2007
BloombergInvestors are betting Bristol-Myers and Sanofi will win the case, since the patent covers the main compound in Plavix, clopidogrel bisulfate.

Sanofi-Aventis Sales Rise 5%, But Profit Slips; Forecasts Flat EPS ...  -  Feb 13, 2007
Trading Markets,Total sales were 5% higher, on a reported basis, impacted by a generic of clopidogrel bisulfate in the United States. Unveiling a flat outlook for 2007,

Sanofi-aventis 2006: In a Difficult Environment, Another Year of ...  -  Feb 12, 2007
Yahoo! News (press release)On August 8, 2006, Apotex announced that it had launched a generic version of clopidogrel bisulfate 75 mg tablets in competition with Plavix® in the United

Sanofi-aventis 2006: In a Difficult Environment, Another Year of ...  -  Feb 12, 2007
PR Newswire (press release),In the last week of December, the share of total clopidogrel bisulfate prescriptions taken by Plavix(R) was rising sharply, reaching 44.3%(8), compared with

Sanofi-Aventis net drops 5% on Plavix decline  -  Feb 13, 2007
MarketWatchIn the last week of December, the share of total clopidogrel bisulfate prescriptions taken reached 44%, up from 21% in the last week of September.

2006: In a difficult environment, another year of growth in ...  -  Feb 13, 2007
Newsdesk,Fourth-quarter sales impacted by a generic of clopidogrel bisulfate in the United States.  Adjusted EPS of €1.02, down 5.6%, or €1.01 excluding selected

2006: In a difficult environment, another year of growth in ...  -  Feb 13, 2007
CNW Telbec (Communiqués de presse),Fourth-quarter sales impacted by a generic of clopidogrel bisulfate in the United States. - 12.5% growth in "Operating income - current" - Adjusted EPS of

Sizing up Bristol's future  -  Feb 10, 2007
Newark Star Ledger,US District Judge Sidney Stein is expected to rule on whether Sanofi's 1988 patent adequately covers clopidogrel bisulfate, the chemical name for Plavix.

Bristol-Myers Asks Court to Stop Plavix Competitor (Update3)  -  18 Jan 2007
BloombergThe company claims, though, that Plavix's active ingredient, clopidogrel bisulfate, was covered by a patent that expired in 2003. Bristol-Myers and Sanofi

United States: Federal Circuit Affirms Preliminary Injunction To ...  -  Jan 5, 2007
Mondaq News Alerts (subcription),Nevertheless, pursuant to the agreement, Apotex launched its generic clopidogrel bisulfate product. Sanofi responded by filing for a preliminary injunction

Sanofi-Aventis wins Plavix case in Canada  -  Dec 29, 2006
newratings.comApotex cannot market its 75mg clopidogrel bisulfate tablets in Canada without the Notice of Compliance. This ruling is the second Plavix-related win for

Market Report -- In Play (BMY)  -  Dec 29, 2006
MSN MoneyAbsent a Notice of Compliance, Apotex cannot market its 75mg clopidogrel bisulfate tablets in Canada. Briefing.com is the leading Internet provider of live

Canadian Federal Court of Appeals Rules in sanofi-aventis' Favor ...  -  Dec 28, 2006
Drug Newswire (press release),Absent a Notice of Compliance, Apotex cannot market its 75mg clopidogrel bisulfate tablets in Canada. Sanofi-aventis is the world's third largest

Canadian Federal Court of Appeals Rules in sanofi-aventis' Favor ...  -  Dec 28, 2006
PR Newswire (press release),Absent a Notice of Compliance, Apotex cannot market its 75mg clopidogrel bisulfate tablets in Canada. About sanofi-aventis Sanofi-aventis is the world's

Bristol-Myers Claims Canadian Plavix Win  -  Dec 28, 2006
Forbes,...preventing Canadian regulators from allowing the company to sell 75 milligram tablets of clopidogrel bisulfate, the active ingredient in Plavix.

Sanofi, Bristol-Myers Win Plavix Ruling in Canada (Update2)  -  Dec 28, 2006
BloombergPlavix, whose active ingredient is clopidogrel bisulfate, is the world's second-biggest-selling drug, behind Pfizer Inc.'s cholesterol treatment Lipitor.

Canadian court tosses Apotex appeal on generic Plavix  -  Dec 28, 2006
CBC British Columbia,...a Federal Court of Canada judgment that prevented Canadian regulators from allowing the company to sell 75 milligram tablets of clopidogrel bisulfate.

Superior Drug Dissolution with ISP Super DisintegrantsDetailed in ...  -  Dec 21, 2006
PharmaLive.com (press release),...and Venlafaxine HCl), but also for actives with low water solubility (Ciprofloxacin HCl, Fexofenadine HCl, Terbinafine HCl, and Clopidogrel Bisulfate).

Preliminary Injunction Against Apotex Upheld On Appeal  -  Dec 10, 2006
Medical News Today (press release),The injunction ordered Apotex to halt its sales of a generic version of clopidogrel bisulfate that competes with PLAVIX® pending the District Court's

Superior Drug Dissolution with ISP Super DisintegrantsDetailed in ...  -  Dec 21, 2006
PharmaLive.com (press release),...and Venlafaxine HCl), but also for actives with low water solubility (Ciprofloxacin HCl, Fexofenadine HCl, Terbinafine HCl, and Clopidogrel Bisulfate).

Plavix (Clopidogrel) and Aspirin  -  Dec 8, 2006
Angioplasty.Org,...toprol xl 25mg, vytorin 10/20mg and aspirin When I came home for the hospital I purchased the generic form of plavix - clopidogrel bisulfate 75 mg.

In Preliminary Injunction Decision, CAFC Forecasts Post-eBay ...  -  Dec 10, 2006
Patently-O,Generic manufacturer Apotex wants to make something similar to Sanofi’s Plavix (clopidogrel bisulfate) and filed an ANDA alleging that Sanofi’s patents were

Bristol-Myers, Sanofi Win Appeal in Plavix Dispute (Update3)  -  Dec 8, 2006
BloombergPlavix, whose active ingredient is clopidogrel bisulfate, is the world's second-biggest-selling drug, behind Pfizer Inc.'s cholesterol treatment Lipitor.

Bristol-Myers Squibb Company Reports Financial Results for the ...  Oct 26, 2006
The decrease in non-GAAP net earnings in 2006 as compared to 2005 is mainly due to the impact of an at-risk launch of generic clopidogrel bisulfate, the loss ... -Yahoo! News (press release) Sanofi-aventis Announces Third Quarter Sales and Earnings for 2006 ...  Oct 31, 2006
Third quarter of 2006 hit by the launch of a generic version of clopidogrel bisulfate in the United States on August 8, 2006, and by measures to curb ... -MSN Money Sanofi-aventis Announces Third Quarter Sales and Earnings for 2006 ...  Oct 31, 2006
...release are stated on a comparable basis(1). THIRD QUARTER: - Third quarter of 2006 hit by the launch of a generic version of clopidogrel bisulfate in the ... -PR Newswire (press release), Sanofi-aventis Announces Third Quarter Sales and Earnings for 2006 ...  Oct 31, 2006
On August 8, 2006, Apotex announced that it had launched a generic version of clopidogrel bisulfate 75 mg tablets in competition with Plavix(R). On August 31 ... -Drug Newswire (press release), Apotex Asks Patent Appeals Court to Lift Ban on Generic Plavix  Oct 31, 2006
...panel. Apotex has argued that the key ingredient in Plavix, clopidogrel bisulfate, is covered by a patent that has already expired. ... -Bloomberg Sanofi-Aventis Q3 Profit Drops On Lower Sales; Backs FY06 Adj. EPS ...  Oct 31, 2006
19.7% year-over-year to euro 972 million, due to a 42.4% drop in the US In early August, Apotex launched a generic version of clopidogrel bisulfate 75 mg ... -Trading Markets, Bristol-Myers falling profits caused by generic competition  Oct 27, 2006
Bristol-Myers Squibb had previously reported that Apotex had launched a generic version of Plavix called clopidogrel bisulfate in August 2006. ... -Pharmaceutical Business Review Bristol-Myers Boosts Guidance  Oct 26, 2006
Estimated total US prescription demand for clopidogrel bisulfate increased by 14% from a year ago, while estimated total US prescription demand for branded ... -TheStreet.com Bristol-Myers Squibb Q3 Profit Plummets On Reduction In Plavix ...  Oct 26, 2006
The company attributed the decrease to the impact of an at-risk launch of generic clopidogrel bisulfate by the Canadian company Apotex Inc., the loss of patent ... -Trading Markets, Bristol-Myers not for sale: Interim CEO  Oct 26, 2006
5 when privately held Canadian drugmaker Apotex started producing generic versions of Plavix - known as clopidogrel bisulfate - cutting into Bristol's sales ... -CNNMoney.com Plavix Ruling Bodes Well For Bristol In Patent Trial  Oct 17, 2006
The companies already had stipulated that Apotex's generic product infringes the patent for Plavix, which is known by the generic name clopidogrel bisulfate. ... -Easy Bourse (Communiqués de presse), Preliminary Injunction Against Apotex Upheld On Appeal  -  Dec 10, 2006
Medical News Today (press release),The injunction ordered Apotex to halt its sales of a generic version of clopidogrel bisulfate that competes with PLAVIX® pending the District Court's

Preliminary Injunction Against Apotex Upheld on Appeal  -  Dec 8, 2006
PR Newswire (press release),The injunction ordered Apotex to halt its sales of a generic version of clopidogrel bisulfate that competes with PLAVIX(R) pending the District Court's

Plavix (Clopidogrel) and Aspirin  -  Dec 8, 2006
Angioplasty.Org,...toprol xl 25mg, vytorin 10/20mg and aspirin When I came home for the hospital I purchased the generic form of plavix - clopidogrel bisulfate 75 mg.

In Preliminary Injunction Decision, CAFC Forecasts Post-eBay ...  -  Dec 10, 2006
Patently-O,Generic manufacturer Apotex wants to make something similar to Sanofi’s Plavix (clopidogrel bisulfate) and filed an ANDA alleging that Sanofi’s patents were

Bristol-Myers, Sanofi Win Appeal in Plavix Dispute (Update3)  -  Dec 8, 2006
BloombergPlavix, whose active ingredient is clopidogrel bisulfate, is the world's second-biggest-selling drug, behind Pfizer Inc.'s cholesterol treatment Lipitor.

Update on Plavix(R) Litigation Settlement  Jun 25, 2006
...announced proposed settlement the companies reached with Apotex relating to patent infringement litigation on Plavix(R) (clopidogrel bisulfate), the companies ... -Finanzen.net

Update on Plavix(R) Litigation Settlement  Jun 25, 2006
...announced proposed settlement the companies reached with Apotex relating to patent infringement litigation on Plavix® (clopidogrel bisulfate), the companies ... -Yahoo! News

Apotex modifies agreement with Sanofi, Bristol  Jun 25, 2006
Under the terms of the modified agreement, Apotex's license to manufacture and sell its "clopidogrel bisulfate" product in the United States would be effective ... -Reuters

Sanofi-aventis & Bristol-Myers Amend Agreement With Apotex On ...  Jun 25, 2006
The company stated that under the terms of the modified agreement, Apotex's license to manufacture and sell its FDA approved clopidogrel bisulfate product in ... -Trading Markets



Merck Q1 Profit Rises On Strong US Zocor, Singulair Sales; Guides ...  Apr 20, 2006
The lawsuit is related to the validity of a composition of matter patent for clopidogrel bisulfate, a medicine made available in US by sanofi-aventis and ... - Trading Markets



FDA Grants Priority Review To Plavix® (Clopidogrel Bisulfate) ...  Jan 30, 2006
FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent Plavix® (clopidogrel bisulfate) for treatment of patients ... - Medical News Today

FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) ...  Jan 17, 2006
FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX(R) (clopidogrel bisulfate) for treatment of patients ... - Boursorama

FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) ...  Jan 17, 2006
FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) for treatment of patients ... - Yahoo! News

(CN) - REMY COINTREAU : Consolidated turnover for the nine months  Jan 17, 2006
...[+]. (PRN) - FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack ... ... - Bolsamania.com

(PRN) - Following Is a Test Release ... [+]  Jan 17, 2006
...(PRN) - FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack ... [+. ... - Bolsamania.com

Sanofi-aventis Posts Dynamic Growth in 2005 Full-Year Consolidated ...  Jan 30, 2006
...clopidogrel. Clopidogrel bisulfate continues to be protected by a valid patent. The patent trial is scheduled to begin on April 3, 2006. ... - Yahoo! News

Plavix Facing Generic Challenge  Jan 24, 2006
Instead, the agency simply placed on its Web site, among all medication listings, the drug's generic name, clopidogrel bisulfate, the dosage strength and the ... - TheStreet.com

FDA offers rapid review for Sanofi/Bristol heart drug  Jan 19, 2006
The supplemental new drug application for Plavix (clopidogrel bisulfate) is designed to allow the product to be used for the treatment of a type of heart ... - Pharmaceutical Business Review

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional